Logo der Universität Basel

Research Database / FORSCHUNGSDATENBANK 
PRINTDOC
 
Publication 4651058 | Verified
 

Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Combining metformin with lactate transport inhibitors as a treatment modality for cancer-recommendation proposal
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4651058
Author(s) Benjamin, Don; Hall, Michael N.
Author(s) at UniBasel Hall, Michael N.
Year 2022
Year: comment 2022
Title Combining metformin with lactate transport inhibitors as a treatment modality for cancer-recommendation proposal
Journal Frontiers in Oncology
Volume 12
Pages / Article-Number 1034397
Keywords cancer; metformin; monocarboxylate transporter; lactic acid; MCT4; syrosingopine
Abstract Highly glycolytic cancer cells excrete lactate to maintain cellular homeostasis. Inhibiting lactate export by pharmacological targeting of plasma membrane lactate transporters is being pursued as an anti-cancer therapy. Work from many laboratories show that the simultaneous inhibition of lactate export and mitochondrial respiration elicits strong synthetic lethality. The mitochondrial inhibitor, metformin, has been the subject of numerous clinical trials as an anti-cancer agent. We propose that, in future clinical trials, metformin be combined with lactate transport inhibitors to exploit this synergistic interaction.
Publisher Frontiers Media
ISSN/ISBN 2234-943X
edoc-URL https://edoc.unibas.ch/90267/
Full Text on edoc Available
Digital Object Identifier DOI 10.3389/fonc.2022.1034397
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/36353534
ISI-Number 000880627100001
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.351 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
02/05/2024